Federal Supply Schedule 36F79723D0129
Award Date
6/1/23
Last Date to Order
5/31/28
Federal Agency
Veterans Integrated Service Network 12
Awardee
Sanofi-Aventis U.s. LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...
The key points from the provided information are as follows: This is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12, a civilian federal agency, to Pierre Fabre Pharmaceuticals, Inc. The contract is for the provision of drugs, pharmaceuticals, and hematology-related products under the FSS-61-IB schedule. The contract has a ceiling value of $4,275,460.00 and a period of performance from May 15, 2019 to September 26, 2024. This is a multiple award...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Provention Bio Inc. to provide the pharmaceutical product TZIELD. The $5 million BPA has a period of performance through June 2024 and is one of two BPAs awarded against Provention Bio's existing $5 million Federal Supply Schedule 65 I B contract, which was initially awarded in July 2023 for a 5-year term. An additional $1.44 million BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
This Federal Supply Schedule contract award, with a ceiling value of $48,300,000.00, was made by the Veterans Integrated Service Network 12 (VISN 12) to Tersera Therapeutics LLC, a for-profit limited liability company manufacturer of goods. The contract, which has a period of performance ending on March 14, 2029, is for the delivery of Drugs, Pharmaceuticals, & Hematology Related Products under the 65 I B Federal Supply Schedule category. As a multiple award Federal Supply Schedule contract,...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...
This is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency, to Biocon Biologics Inc., a foreign-owned for-profit manufacturer. The contract is for the provision of pharmaceutical and drug products under the FSS-61-IB Pharmaceuticals and Drugs schedule, with a ceiling value of $750,000 and a period of performance from March 1, 2024 to February 28, 2029. The contract does not have any set-aside requirements and was awarded...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79723D0129-36E79724A0021 | Sanofi-Aventis U.s. LLC | $5.0m | 7/1/24 | 6/30/26 | 5/23/25 |